Hemolytic Uremic Syndrome News and Research

RSS

Acute renal failure in young children is most commonly linked to hemolytic uremic syndrome (HUS). In this situation, it often comes as a shock, occurring as it does in a child who was previously healthy but is now in mortal danger. This illness is caused by the toxin produced by certain bacterial strains, most commonly found in beef.

Findings on cell working could lead to test and therapy for kidney failure caused by E. coli

New findings by St. Michael's researchers about the way cells work could lead to a test and therapy for kidney failure caused by E. coli

11 Jan 2012

EC extends therapeutic indication for Soliris to treat atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the European Commission (EC) has extended the therapeutic indication for Soliris® (eculizumab) to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS).

29 Nov 2011

Almac collaborates with Alexion for packaging and distribution of Soliris during German E. coli outbreak

Almac, a leading provider of contract services to the global pharmaceutical and biotech industries, responded earlier this year to an urgent request from their client partner, Alexion Pharmaceuticals, Inc., a global biotechnology company, for packaging and distribution of Soliris (eculizumab) for patients with STEC-HUS during the E. coli outbreak in Germany earlier this year.

21 Nov 2011

Alexion third quarter total revenues increase to $204.0 million

Alexion Pharmaceuticals, Inc. today announced financial results for the three and nine months ended September 30, 2011.

20 Oct 2011

Alexion receives FDA approval for Soliris to treat atypical Hemolytic Uremic Syndrome

The U.S. Food and Drug Administration today approved Soliris (eculizumab) to treat patients with atypical Hemolytic Uremic Syndrome (aHUS), a rare and chronic blood disease that can lead to kidney (renal) failure and is also associated with increased risk of death and stroke.

26 Sep 2011

EMA CHMP adopts positive opinion for Soliris to treat atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that the therapeutic indication for Soliris® (eculizumab) be extended to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS) in Europe.

23 Sep 2011

High risk of serious complications or death in children with SP-HUS

Hemolytic uremic syndrome (HUS) caused by infection with pneumococcal bacteria leads to severe illness—with a high rate of irreversible kidney damage—in infants and young children, reports a study in the September issue of The Pediatric Infectious Disease Journal.

30 Aug 2011

Intravenous fluids appear to lower severity of kidney failure in children with E. coli infection

Infection with E. coli bacteria can wreak havoc in children, leading to bloody diarrhea, fever and kidney failure. But giving children intravenous fluids early in the course of an E. coli O157:H7 infection appears to lower the odds of developing severe kidney failure, according to researchers at Washington University School of Medicine in St. Louis and other institutions.

25 Jul 2011

Alexion second quarter net product sales of Soliris increase to $185.7 million

Alexion Pharmaceuticals, Inc. today announced financial results for the three and six months ended June 30, 2011. Alexion Pharmaceuticals, Inc. reported net product sales of Soliris of $185.7 million in Q2, reflecting steady addition of new patients, compared to $125.8 million for the same period in 2010.

21 Jul 2011

New strategy can prevent onset of E. coli related illness

The recent outbreak of E. coli infection in Germany has put a potentially fatal bacterium back on everyone's radar screen. While some researchers are looking for a better way to treat the disease, professor Debora Foster of the Department of Chemistry and Biology at Ryerson University is taking a different approach.

11 Jul 2011

Arizona E. coli related death triggers warning

The Center for Disease Control and Prevention (CDC) and the Arizona Department of Health announced last Friday that a man who recently traveled to Germany was infected by the German E. coli outbreak. The man died from kidney complications. This death was the first U.S. fatality of the relentless epidemic. According to the World Health Organization, 52 have been killed in the outbreak.

10 Jul 2011

Alexion begins eculizumab clinical trial in Shiga-toxin producing E. coli hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl (APIS), announced today that the Paul-Ehrlich-Institut, Germany's healthcare regulatory body for biological products, has authorized initiation of an open-label clinical trial to investigate eculizumab as a treatment for patients with Shiga-toxin producing E. coli hemolytic uremic syndrome, which has resulted from infections by Enterohemorrhagic Escherichia coli in an unusually wide outbreak in Germany that began in May.

20 Jun 2011

Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011

Alexion Pharmaceuticals, Inc. today announced the presentation of final data from the two Phase 2 studies of Soliris as a treatment for patients with atypical hemolytic uremic syndrome.

13 Jun 2011

German hospital adopts Luminex new diagnostic assay to manage current E.coli outbreak

Luminex Corporation and the Kliniken der Stadt Koln, Institute of Pathology and Institute for Hygiene today announced that Luminex's newly released xTAG Gastrointestinal Pathogen Panel (GPP) is being used successfully as a first-line screen for patients at Kliniken der Stadt Koln suspected of having an E. coli infection.

From Luminex 10 Jun 2011

Pall's GeneDisc System helps German authorities screen for deadly E.coli strain

Pall Corporation's GeneDisc System is helping German authorities screen for a deadly strain of E.coli that has sickened nearly 3000 people and disrupted that nation's food industry. Pall's GeneDisc technology is being used by Germany's national reference laboratory to expedite testing of food samples for the toxic strain of the pathogen known as E.coli O104:H4.

From Pall Corporation 10 Jun 2011

Health officials rule out sprouts as source of German E. coli outbreak

Health officials in Germany are continuing to search for the source of an E. coli outbreak after tests on suspected sprouts from a farm in the north of the country came back negative, Deutsche Welle reports. The outbreak has killed 22 people and sickened more than 2,000 (Hallam/Penfold, 6/6).

8 Jun 2011

New E. coli outbreak alarms Europe

An Escherichia coli (E. coli) outbreak of disease in Germany has left 22 people dead and it is alarming populations across Europe.

5 Jun 2011

Preliminary data from Ion PGM sequencer reveals German E. coli outbreak is a new hybrid strain

Life Technologies Corporation today announced that preliminary data from DNA sequencing performed in cooperation with the University Hospital Muenster, Germany, on the Ion Personal Genome Machine strongly suggests that the bacterium at the root of the deadly outbreak in Germany is a new hybrid type of pathogenic E. coli strains.

4 Jun 2011

BGI genome sequencing identifies new super-toxic bacteria as cause of current European epidemic

The recent outbreak of an E. coli infection in Germany has resulted in serious concerns about the potential appearance of a new deadly strain of bacteria.

4 Jun 2011

European E. coli strain never seen before in humans, scientists say

The food safety office of the WHO on Thursday announced that the bacterium responsible for the E. coli outbreak in Europe is a strain never seen before in humans and could mean "the infection could prove unusually difficult to bring under control," Nature News reports.

4 Jun 2011

Hemolytic Uremic Syndrome News and Research

Further Reading

Findings on cell working could lead to test and therapy for kidney failure caused by E. coli

EC extends therapeutic indication for Soliris to treat atypical hemolytic uremic syndrome

Almac collaborates with Alexion for packaging and distribution of Soliris during German E. coli outbreak

Alexion third quarter total revenues increase to $204.0 million

Alexion receives FDA approval for Soliris to treat atypical Hemolytic Uremic Syndrome

EMA CHMP adopts positive opinion for Soliris to treat atypical hemolytic uremic syndrome

High risk of serious complications or death in children with SP-HUS

Intravenous fluids appear to lower severity of kidney failure in children with E. coli infection

Alexion second quarter net product sales of Soliris increase to $185.7 million

New strategy can prevent onset of E. coli related illness

Arizona E. coli related death triggers warning

Alexion begins eculizumab clinical trial in Shiga-toxin producing E. coli hemolytic uremic syndrome

Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011

German hospital adopts Luminex new diagnostic assay to manage current E.coli outbreak

Pall's GeneDisc System helps German authorities screen for deadly E.coli strain

Health officials rule out sprouts as source of German E. coli outbreak

New E. coli outbreak alarms Europe

Preliminary data from Ion PGM sequencer reveals German E. coli outbreak is a new hybrid strain

BGI genome sequencing identifies new super-toxic bacteria as cause of current European epidemic

European E. coli strain never seen before in humans, scientists say

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News